Knowles (KN) Q4 2025 earnings review
Transformation Complete: Industrial Pivot Pays Off
Knowles has successfully shed its consumer electronics skin (Consumer MEMS divested Dec 2024) and the remaining industrial/medtech core is sprinting. Q4 Revenue grew 14% YoY to $162M, beating the high end of guidance. The star was the Precision Devices (PD) segment, surging 23% YoY as channel inventory issues evaporated and defense/medtech demand spiked. Margins expanded, and the company enters 2026 with a clean balance sheet (0.4x net leverage). While Q1 2026 guidance implies a sequential seasonal dip, the year-over-year growth trajectory remains intact.
🐂 Bull Case
The PD segment is firing on all cylinders, growing 23.2% YoY with margins expanding 290 bps. This confirms that the destocking headwinds from early 2025 are over and underlying demand in Defense and EV is real.
With the divestiture complete, Knowles holds $54M in cash against low debt ($0.4x leverage ratio). The board authorized an additional $150M buyback earlier in the year, and they repurchased $65M in FY25. The balance sheet is primed for M&A or returns.
🐻 Bear Case
MedTech & Specialty Audio (MSA)—historically the steady grower—slowed to 4% YoY growth in Q4 (down from 10% in Q2). Margins in this segment were flat, indicating limited pricing power or mix headwinds.
Operating Cash Flow fell 12% YoY in FY25 ($114M vs $130M). While management blames the divestiture mechanics, investors need to see clean cash generation in FY26 to validate the 'high margin industrial' narrative.
⚖️ Verdict: 🟢
Bullish. The strategic pivot is validated by the numbers. Accelerating revenue growth and expanding margins in the largest segment (PD) outweigh the noise from the divestiture. Valuation should re-rate as a pure-play industrial tech company.
Key Themes
Precision Devices (PD) Breakout
PD has shifted from a recovery story to a growth engine. Revenue surged 23.2% YoY to $89.7M. More importantly, Adjusted EBITDA margin jumped to 23.4% from 20.5% a year ago. This segment now accounts for ~55% of total revenue, meaning its acceleration moves the needle for the entire company.
Inventory Normalization Complete
The rapid acceleration in PD revenue (+23% vs +12% in Q3) confirms that the distribution channel destocking, which plagued the company in late 2024/early 2025, is finished. Demand is now matching end-market consumption.
MedTech (MSA) Margin Stagnation
Despite the 'Specialty' narrative, MSA margins are stuck. Adjusted EBITDA margin was 42.6%, barely moving from 42.5% a year ago. With growth slowing to 4%, this segment risks becoming a 'cash cow' rather than a growth driver. We need to see if the new 'inductor product line' mentioned in previous quarters can actually revive growth here.
M&A Firepower
Net leverage is negligible at 0.4x. Management explicitly mentioned a 'robust pipeline' and 'demonstrated capabilities to acquire.' With organic growth now stabilizing, expect Knowles to use its balance sheet for bolt-on acquisitions in Defense or MedTech to sustain the double-digit growth narrative.
Cash Flow Quality
FY25 Free Cash Flow conversion was messy. While Adjusted FCF margin was healthy at 19.3%, raw Net Cash from Operations dropped 12% YoY. Management cites the CMM divestiture (loss of cash flows + transaction costs), but this creates a 'show me' situation for H1 2026.
Other KPIs
Accelerating. Up from 44.1% a year ago and 44.2% in Q2. This expansion confirms the thesis that shedding the consumer business would accrete margins. The mix shift toward the higher-margin PD segment is working.
Stable. Represents 19.3% of revenue, comfortably within the 16-20% target range. However, CapEx ramped significantly to $32.1M (vs $13.6M in FY24) as they invest in capacity for the 'specialty film' opportunities.
Stable at 6.5% of revenue. The company is maintaining investment discipline while growing the top line, contributing to the operating leverage seen in the quarter.
Guidance
Decelerating sequentially (-9% at midpoint vs 25Q4) but Accelerating YoY (+12% vs 25Q1). The sequential drop is typical Q1 seasonality, but the double-digit YoY growth forecast confirms the momentum is real.
Accelerating. At the midpoint ($0.24), this represents +33% growth vs 25Q1 ($0.18). The company is successfully driving operating leverage on higher volumes.
Key Questions
Precision Devices Sustainability
PD growth jumped from 12% in Q3 to 23% in Q4. How much of this was channel refill versus true end-market demand? Can we expect >15% growth to persist in 2026?
MSA Margin Ceiling
MedTech margins have stalled at ~42-43%. With the high-margin hearing health business recovering, why aren't we seeing more leverage here? Is pricing pressure increasing?
Tax Rate Headwinds
The Q1 26 GAAP to Non-GAAP bridge suggests a normalized tax impact. Previous calls mentioned a tax rate hike in 2026. What is the full-year effective tax rate assumption baked into the outlook?